Haemonetics Corporation (HAE)
NYSE: HAE
· Real-Time Price · USD
48.55
-1.21 (-2.43%)
At close: Oct 15, 2025, 3:59 PM
48.58
0.06%
After-hours: Oct 15, 2025, 04:20 PM EDT
-2.43% (1D)
| Bid | 48.56 |
| Market Cap | 2.34B |
| Revenue (ttm) | 1.35B |
| Net Income (ttm) | 163.34M |
| EPS (ttm) | 3.27 |
| PE Ratio (ttm) | 14.85 |
| Forward PE | 10.4 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 51.05 |
| Volume | 526,077 |
| Avg. Volume (20D) | 1,011,200 |
| Open | 49.55 |
| Previous Close | 49.76 |
| Day's Range | 48.55 - 50.02 |
| 52-Week Range | 47.32 - 94.99 |
| Beta | 0.36 |
| Ex-Dividend Date | n/a |
Analyst Forecast
According to 0 analyst ratings, the average rating for HAE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsHaemonetics Corporation is scheduled to release its earnings on
Nov 6, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
-26.58%
Haemonetics shares are trading lower following the...
Unlock content with
Pro Subscription
5 months ago
+5.85%
Haemonetics shares are trading higher after the company reported better-than-expected Q4 financial results.
2 months ago · seekingalpha.com
I'm Recommending Haemonetics Again, But With Caveats (Ratings Upgrade)Haemonetics Corporation remains a high-quality blood-management franchise with strong TEG and plasma software moats, but recent growth has paused due to portfolio shifts and competition. Q1 FY2026 res...
